Biotie's Annual Financial Report and Corporate Governance Statement 2010 published

BIOTIE THERAPIES CORP.    STOCK EXCHANGE RELEASE 25 March 2011 at 9.10 a.m.

Biotie's Annual Financial Report and Corporate Governance Statement 2010
published

Biotie Therapies Corp.' s  Annual financial report for the financial period
ended 31 December 2010 as well as Corporate Governance Statement 2010 have been
published.

The documents are attached in pdf format in this release. Both documents are
also available at Biotie's website www.biotie.com in English and Finnish
language.

Turku, 25 March 2011

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail:virve.nurmi@biotie.com

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com

Biotie Therapies Corp.

Biotie is a specialized drug development company focused on the development of
drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease,
Alzheimer's disease and other cognitive disorders, bipolar disorder, addictions
and drug dependence) and inflammatory diseases (rheumatoid arthritis, psoriasis,
chronic obstructive pulmonary disease and others).

It has several innovative small molecule and biological drug candidates at
different stages of clinical development. Biotie's products address diseases
with high unmet medical need and significant market potential.

 Some of the programmes have been validated through licensing agreements for
development and commercialization with top-tier pharmaceutical partners
including H. Lundbeck A/S, UCB Pharma S.A.and Seikagaku Corporation. The most
advanced product, nalmefene for alcohol dependence, is currently in phase III
clinical development by licensing partner H. Lundbeck A/S.

 Shares are listed on NASDAQ OMX Helsinki Ltd.




[HUG#1499904]